BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 16813529)

  • 1. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.
    Blair HC; Borysenko CW; Villa A; Schlesinger PH; Kalla SE; Yaroslavskiy BB; Garćia-Palacios V; Oakley JI; Orchard PJ
    J Bone Miner Res; 2004 Aug; 19(8):1329-38. PubMed ID: 15231021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
    Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
    J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).
    Alatalo SL; Ivaska KK; Waguespack SG; Econs MJ; Väänänen HK; Halleen JM
    Clin Chem; 2004 May; 50(5):883-90. PubMed ID: 15016726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
    Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
    J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro.
    Flanagan AM; Massey HM; Wilson C; Vellodi A; Horton MA; Steward CG
    Bone; 2002 Jan; 30(1):85-90. PubMed ID: 11792569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
    Kudo O; Sabokbar A; Pocock A; Itonaga I; Athanasou NA
    Calcif Tissue Int; 2002 Dec; 71(6):539-46. PubMed ID: 12232680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts.
    Del Fattore A; Fornari R; Van Wesenbeeck L; de Freitas F; Timmermans JP; Peruzzi B; Cappariello A; Rucci N; Spera G; Helfrich MH; Van Hul W; Migliaccio S; Teti A
    J Bone Miner Res; 2008 Mar; 23(3):380-91. PubMed ID: 17997709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.
    Henriksen K; Gram J; Høegh-Andersen P; Jemtland R; Ueland T; Dziegiel MH; Schaller S; Bollerslev J; Karsdal MA
    Am J Pathol; 2005 Nov; 167(5):1341-8. PubMed ID: 16251418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
    Guerrini MM; Sobacchi C; Cassani B; Abinun M; Kilic SS; Pangrazio A; Moratto D; Mazzolari E; Clayton-Smith J; Orchard P; Coxon FP; Helfrich MH; Crockett JC; Mellis D; Vellodi A; Tezcan I; Notarangelo LD; Rogers MJ; Vezzoni P; Villa A; Frattini A
    Am J Hum Genet; 2008 Jul; 83(1):64-76. PubMed ID: 18606301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine and paracrine nitric oxide regulate attachment of human osteoclasts.
    Yaroslavskiy BB; Li Y; Ferguson DJ; Kalla SE; Oakley JI; Blair HC
    J Cell Biochem; 2004 Apr; 91(5):962-72. PubMed ID: 15034931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopetrosis with micro-lacunar resorption because of defective integrin organization.
    Blair HC; Yaroslavskiy BB; Robinson LJ; Mapara MY; Pangrazio A; Guo L; Chen K; Vezzoni P; Tolar J; Orchard PJ
    Lab Invest; 2009 Sep; 89(9):1007-17. PubMed ID: 19546854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes.
    Chu K; Koller DL; Snyder R; Fishburn T; Lai D; Waguespack SG; Foroud T; Econs MJ
    Bone; 2005 Nov; 37(5):655-61. PubMed ID: 16120485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
    Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
    J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
    Neale SD; Smith R; Wass JA; Athanasou NA
    Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function.
    Rajapurohitam V; Chalhoub N; Benachenhou N; Neff L; Baron R; Vacher J
    Bone; 2001 May; 28(5):513-23. PubMed ID: 11344051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.
    Karsdal MA; Henriksen K; Sørensen MG; Gram J; Schaller S; Dziegiel MH; Heegaard AM; Christophersen P; Martin TJ; Christiansen C; Bollerslev J
    Am J Pathol; 2005 Feb; 166(2):467-76. PubMed ID: 15681830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.